Physician profile
Bachar Dergham
NPI 1013016930
$386,720.42
in general payments reported to CMS, 2019-2025
30 companies · $46K in 2025
The $46K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $11K · 2021: $35K · 2022: $76K · 2023: $94K · 2024: $75K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $167K · Travel and Lodging: $28K · Consulting Fee: $9,605 · Food and Beverage: $6,215 · Honoraria: $4,550 · Education: $56.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $166,637.00 |
| Travel and Lodging | $28,195.88 |
| Consulting Fee | $9,605.00 |
| Food and Beverage | $6,215.38 |
| Honoraria | $4,550.00 |
| Education | $56.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $100,905.56 | 2019-2023 | Tecentriq |
| Beigene USA, INC. | $90,360.64 | 2023-2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $71,181.43 | 2020-2023 | Imbruvica |
| Beone Medicines USA, INC. | $35,307.58 | 2025 | Brukinsa |
| Janssen Biotech, INC. | $34,028.16 | 2020-2025 | Imbruvica, Rybrevant |
| Kite Pharma, INC. | $14,244.43 | 2020-2023 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $11,236.34 | 2023-2024 | Opdivo |
| Novartis Pharmaceuticals Corporation | $6,170.15 | 2019 | |
| Celgene Corporation | $5,674.88 | 2019-2020 | |
| Novocure INC. | $4,809.91 | 2023-2024 | Optune Lua (Novottf-200t) |
| Acceleron Pharma, INC. | $3,380.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $2,800.00 | 2020 | |
| Karyopharm Therapeutics INC. | $1,967.16 | 2021-2025 | Xpovio |
| Taiho Oncology, INC. | $1,130.00 | 2024 | |
| Partner Therapeutics, INC. | $900.00 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $623.09 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $434.79 | 2023 | Libtayo |
| Geron Corporation | $245.87 | 2025 | Imetelstat |
| Incyte Corporation | $236.91 | 2021 | |
| Emd Serono, INC. | $150.51 | 2024-2025 | |
| Genmab U.S., INC. | $125.00 | 2023 | Epkinly |
| Glaxosmithkline, LLC. | $124.18 | 2021 | |
| Rigel Pharmaceuticals, INC. | $122.27 | 2019 | |
| Pharmacosmos Therapeutics INC. | $120.83 | 2024 | Monoferric |
| Sobi, INC | $114.20 | 2022 | |
| Mirati Therapeutics, INC. | $106.24 | 2023 | Krazati |
| Pfizer INC. | $104.57 | 2024 | |
| Abbvie INC. | $75.00 | 2024 | |
| Gilead Sciences, INC. | $24.34 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $16.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bachar Dergham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.